comparemela.com

Crucell Nv News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oxford Spin-out Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer, as highlighted in ASH plenary

Oxford Spin-out Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer, as highlighted in ASH plenary

- Spin-out from University of Oxford built on a decade of world-leading research on blood cancers and breakthrough innovation in single-cell multi-omic analysis by founders Professor Adam Mead

Oxford Spin-out Alethiomics launches to advance its multi-omics target discovery pipeline in blood cancer, as highlighted in ASH plenary

Covid-19 Vaccines Yield Breakthroughs in Long-Term Fight Against Infectious Disease

Covid-19 Vaccines Yield Breakthroughs in Long-Term Fight Against Infectious Disease     The pandemic has opened a new era for vaccines developed with gene-based technologies, techniques that have long stumped scientists and pharmaceutical companies, suggesting the possibility of future protection against a range of infectious disease. Johnson & Johnson’s Covid-19 vaccine, which was authorized Saturday for use in the U.S., is at the vanguard of a class of shots designed to mobilize a person’s immune defenses against the disease. It will be the first Covid-19 vaccine administered in the U.S. that uses viral-vector technology, which employs an engineered cold virus to ferry coronavirus-fighting genetic code to the body’s cells.

ONA Therapeutics appoints Mark Throsby to its Board of Directors

Share: BARCELONA, Spain, March 5, 2021 /PRNewswire-PRWeb/ Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member of its Board of Directors. Dr. Throsby is a proven senior executive with more than 20 years of experience in the pharma & biotech industry and has led multiple drug discovery programs from conception to the clinic. Mark s experience in developing therapeutic biologics in oncology combined with his know-how of building science-driven companies strengthens the ONA team tremendously as we advance our treatments for metastatic cancer to the clinic, said Valerie Vanhooren, Ph.D., CEO of ONA Therapeutics. I welcome Mark to our team and look forward to working with him.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.